Anti-IL17 and anti-IL23 biologic drugs for genital psoriasis: a single-center retrospective comparative study
Genital psoriasis affects 33-63% patients with psoriasis during the course of disease, usually leading to a severe reduction of patient’s quality of life. This study aims to retrospectively asses the effectiveness of interleukin (IL)-23 and IL-17 inhibitors in a real-life population affected by mod...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2023-05-01
|
| Series: | Dermatology Reports |
| Subjects: | |
| Online Access: | https://www.pagepress.org/journals/index.php/dr/article/view/9692 |
| _version_ | 1797823459185655808 |
|---|---|
| author | Andrea Cortese Luigi Gargiulo Luciano Ibba Giovanni Fiorillo Francesco Toso Carlo Alberto Vignoli Alessandra Narcisi Antonio Costanzo Mario Valenti |
| author_facet | Andrea Cortese Luigi Gargiulo Luciano Ibba Giovanni Fiorillo Francesco Toso Carlo Alberto Vignoli Alessandra Narcisi Antonio Costanzo Mario Valenti |
| author_sort | Andrea Cortese |
| collection | DOAJ |
| description |
Genital psoriasis affects 33-63% patients with psoriasis during the course of disease, usually leading to a severe reduction of patient’s quality of life. This study aims to retrospectively asses the effectiveness of interleukin (IL)-23 and IL-17 inhibitors in a real-life population affected by moderate-to-severe plaque psoriasis with genital involvement coming from our dermatology department. A total of 86 patients with diagnosis of moderate-to-severe plaque psoriasis with severe genital involvement were enrolled. Patient characteristics, Psoriasis Area and Severity Index (PASI), and Static Physician Global Assessment of Genitalia (sPGA-G) at each visit were recorded. During the treatment, the mean PASI decreased from 12,8 at 0,63 at week 52; PGA of 0/1 was reached by 97,40% at week 52 and by 100% of patients (37/37) at week 104. No significant differences between the IL-23 and IL-17 inhibitors were observed; indeed the bio-naive group of patients demonstrated superior response compared to the group of patient bio-experienced. Our findings confirmed that IL-23 and IL-17 inhibitors as a safe and effective therapeutic option for the treatment of genital psoriasis.
|
| first_indexed | 2024-03-13T10:24:19Z |
| format | Article |
| id | doaj.art-eea9109495514714a98505e8de9a444f |
| institution | Directory Open Access Journal |
| issn | 2036-7392 2036-7406 |
| language | English |
| last_indexed | 2024-03-13T10:24:19Z |
| publishDate | 2023-05-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Dermatology Reports |
| spelling | doaj.art-eea9109495514714a98505e8de9a444f2023-05-19T17:57:58ZengPAGEPress PublicationsDermatology Reports2036-73922036-74062023-05-0110.4081/dr.2023.9692 Anti-IL17 and anti-IL23 biologic drugs for genital psoriasis: a single-center retrospective comparative studyAndrea Cortese0Luigi Gargiulo1Luciano Ibba2Giovanni Fiorillo3Francesco Toso4Carlo Alberto Vignoli5Alessandra Narcisi6Antonio Costanzo7Mario Valenti8Department of Biomedical Sciences, Humanitas University, Pieve Emanuele; Dermatology Unit, IRCCS Humanitas Research Hospital, RozzanoDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele; Dermatology Unit, IRCCS Humanitas Research Hospital, RozzanoDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele; Dermatology Unit, IRCCS Humanitas Research Hospital, RozzanoDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele; Dermatology Unit, IRCCS Humanitas Research Hospital, RozzanoDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele; Dermatology Unit, IRCCS Humanitas Research Hospital, RozzanoDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele; Dermatology Unit, IRCCS Humanitas Research Hospital, RozzanoDermatology Unit, IRCCS Humanitas Research Hospital, RozzanoDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele; Dermatology Unit, IRCCS Humanitas Research Hospital, RozzanoDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano Genital psoriasis affects 33-63% patients with psoriasis during the course of disease, usually leading to a severe reduction of patient’s quality of life. This study aims to retrospectively asses the effectiveness of interleukin (IL)-23 and IL-17 inhibitors in a real-life population affected by moderate-to-severe plaque psoriasis with genital involvement coming from our dermatology department. A total of 86 patients with diagnosis of moderate-to-severe plaque psoriasis with severe genital involvement were enrolled. Patient characteristics, Psoriasis Area and Severity Index (PASI), and Static Physician Global Assessment of Genitalia (sPGA-G) at each visit were recorded. During the treatment, the mean PASI decreased from 12,8 at 0,63 at week 52; PGA of 0/1 was reached by 97,40% at week 52 and by 100% of patients (37/37) at week 104. No significant differences between the IL-23 and IL-17 inhibitors were observed; indeed the bio-naive group of patients demonstrated superior response compared to the group of patient bio-experienced. Our findings confirmed that IL-23 and IL-17 inhibitors as a safe and effective therapeutic option for the treatment of genital psoriasis. https://www.pagepress.org/journals/index.php/dr/article/view/9692biologicsgenital psoriasispsoriasis treatment |
| spellingShingle | Andrea Cortese Luigi Gargiulo Luciano Ibba Giovanni Fiorillo Francesco Toso Carlo Alberto Vignoli Alessandra Narcisi Antonio Costanzo Mario Valenti Anti-IL17 and anti-IL23 biologic drugs for genital psoriasis: a single-center retrospective comparative study Dermatology Reports biologics genital psoriasis psoriasis treatment |
| title | Anti-IL17 and anti-IL23 biologic drugs for genital psoriasis: a single-center retrospective comparative study |
| title_full | Anti-IL17 and anti-IL23 biologic drugs for genital psoriasis: a single-center retrospective comparative study |
| title_fullStr | Anti-IL17 and anti-IL23 biologic drugs for genital psoriasis: a single-center retrospective comparative study |
| title_full_unstemmed | Anti-IL17 and anti-IL23 biologic drugs for genital psoriasis: a single-center retrospective comparative study |
| title_short | Anti-IL17 and anti-IL23 biologic drugs for genital psoriasis: a single-center retrospective comparative study |
| title_sort | anti il17 and anti il23 biologic drugs for genital psoriasis a single center retrospective comparative study |
| topic | biologics genital psoriasis psoriasis treatment |
| url | https://www.pagepress.org/journals/index.php/dr/article/view/9692 |
| work_keys_str_mv | AT andreacortese antiil17andantiil23biologicdrugsforgenitalpsoriasisasinglecenterretrospectivecomparativestudy AT luigigargiulo antiil17andantiil23biologicdrugsforgenitalpsoriasisasinglecenterretrospectivecomparativestudy AT lucianoibba antiil17andantiil23biologicdrugsforgenitalpsoriasisasinglecenterretrospectivecomparativestudy AT giovannifiorillo antiil17andantiil23biologicdrugsforgenitalpsoriasisasinglecenterretrospectivecomparativestudy AT francescotoso antiil17andantiil23biologicdrugsforgenitalpsoriasisasinglecenterretrospectivecomparativestudy AT carloalbertovignoli antiil17andantiil23biologicdrugsforgenitalpsoriasisasinglecenterretrospectivecomparativestudy AT alessandranarcisi antiil17andantiil23biologicdrugsforgenitalpsoriasisasinglecenterretrospectivecomparativestudy AT antoniocostanzo antiil17andantiil23biologicdrugsforgenitalpsoriasisasinglecenterretrospectivecomparativestudy AT mariovalenti antiil17andantiil23biologicdrugsforgenitalpsoriasisasinglecenterretrospectivecomparativestudy |